6 days ago
Braves predicted to sign $85M ex-Cubs Gold Glove finalist with power bat after career-best season originally appeared on The Sporting News. Add The Sporting News as a Preferred Source by clicking here.
The Atlanta Braves won the NL East last season and nearly reached 100 wins, which was a great accomplishment. However, the beginning of the season was plagued by injuries and a suspension.
The Braves signed Jurickson Profar two offseasons ago, but the move has been nothing but detrimental. In fact, he has missed 243 games due to suspensions, including a year-long suspension in 2026.
"Atlanta Braves designated hitter Jurickson Profar is facing a 162-game suspension after testing positive for a performance-enhancing drug for the second time in the last year, sources told ESPN on Tuesday. Profar, 33, is the sixth player to receive a 162-game ban for PED use since Major League Baseball increased the penalty for two-time offenders to a full season in 2014. He will forfeit the entirety of his $15 million salary," ESPN's Jeff Passan wrote.
Heading into the offseason, one of the biggest questions for Atlanta will be how it addresses left field.
#season #sporting
The Atlanta Braves won the NL East last season and nearly reached 100 wins, which was a great accomplishment. However, the beginning of the season was plagued by injuries and a suspension.
The Braves signed Jurickson Profar two offseasons ago, but the move has been nothing but detrimental. In fact, he has missed 243 games due to suspensions, including a year-long suspension in 2026.
"Atlanta Braves designated hitter Jurickson Profar is facing a 162-game suspension after testing positive for a performance-enhancing drug for the second time in the last year, sources told ESPN on Tuesday. Profar, 33, is the sixth player to receive a 162-game ban for PED use since Major League Baseball increased the penalty for two-time offenders to a full season in 2014. He will forfeit the entirety of his $15 million salary," ESPN's Jeff Passan wrote.
Heading into the offseason, one of the biggest questions for Atlanta will be how it addresses left field.
#season #sporting
6 days ago
Green Bay Packers wide receiver Christian Watson took an ambulance ride to a local hospital after suffering an injury during Thursday night's win over the Carolina Panthers, but precautionary testing on Watson's chest came back with good news, so he rode the ambulance back to Lambeau Field and finished the game without complication.
Watson explained the wild sequence, which started with him landing hard on the football at the end of his 53-yard catch in the second quarter and ended with Watson returning in the same ambulance he took to the hospital, running back onto the field to the roar of the crowd and catching two passes after being cleared to return from the frightening injury.
From Watson in the post-game locker room: "I think I just came down on the ball, or my elbow or something. I couldn't breathe on the field, got the wind knocked out of me. Got back to the sideline and was spitting up blood, so the doctor said I had to go get a CT. I was begging him to not make me do that, but it is what it is. Everything looked good, just got a rib, that's all, all the major stuff was all good, no internal bleeding or anything like that, so I was able to get back out there."
Watson said he has a broken rib. He wore extra padding and a molding around his ribs to protect the injury when he returned.
On the Prime Video broadcast, Watson told Kaylee Hartung that he was checking the doctor's play-by-play of the game while at the hospital. He was gone from the stadium for roughly an hour while being evaluated.
#back #ambulance #hospital #game
Watson explained the wild sequence, which started with him landing hard on the football at the end of his 53-yard catch in the second quarter and ended with Watson returning in the same ambulance he took to the hospital, running back onto the field to the roar of the crowd and catching two passes after being cleared to return from the frightening injury.
From Watson in the post-game locker room: "I think I just came down on the ball, or my elbow or something. I couldn't breathe on the field, got the wind knocked out of me. Got back to the sideline and was spitting up blood, so the doctor said I had to go get a CT. I was begging him to not make me do that, but it is what it is. Everything looked good, just got a rib, that's all, all the major stuff was all good, no internal bleeding or anything like that, so I was able to get back out there."
Watson said he has a broken rib. He wore extra padding and a molding around his ribs to protect the injury when he returned.
On the Prime Video broadcast, Watson told Kaylee Hartung that he was checking the doctor's play-by-play of the game while at the hospital. He was gone from the stadium for roughly an hour while being evaluated.
#back #ambulance #hospital #game
7 days ago
The Green Bay Packers (5-3) overcame an ugly start and an unnecessarily stressful finish by dominating the Carolina Panthers (3-4) for the rest of the contest, and Jordan Love's three touchdown passes allowed Matt LaFleur's team to escape with a 27-19 win on "Thursday Night Football" to open Week 8.
Instant ***** ysis of the Packers' win over the Panthers on TNF:
It was over when...
Christian Watson, who missed time while getting precautionary tests at a local hospital, moved the chains on third down late in the fourth quarter, allowing the Packers to kill off most of the remaining clock and end any chances of a final comeback attempt.
WR Christian Watson: His 10 targets created eight catches and 113 yards, including a 53-yarder that sparked a scoring drive. He had a scary injury coming down with the deep ball, had to go to the hospital for testing and still returned to make an impact in the second half.
#carolina #jordan
Instant ***** ysis of the Packers' win over the Panthers on TNF:
It was over when...
Christian Watson, who missed time while getting precautionary tests at a local hospital, moved the chains on third down late in the fourth quarter, allowing the Packers to kill off most of the remaining clock and end any chances of a final comeback attempt.
WR Christian Watson: His 10 targets created eight catches and 113 yards, including a 53-yarder that sparked a scoring drive. He had a scary injury coming down with the deep ball, had to go to the hospital for testing and still returned to make an impact in the second half.
#carolina #jordan
29 days ago
Students at Cornell University began what was billed as a seven-hour sit-in on Wednesday in solidarity with "Jane Doe," the former student who alleges she was drugged and raped by multiple members of a fraternity on its Ithaca, N.Y., campus in October 2024.
"Seven hours for the seven hours she endured," a coalition of Cornell student groups said in an Instagram post announcing the demonstration. "Seven hours of solidarity. Seven hours demanding change."
About 80 students gathered in a campus dining hall named for Pulitzer Prize-winning author Toni Morrison on Wednesday afternoon, according to NBC News. The protest was part of "Zero Day," which organizers described as an "economic blackout calling on students to disrupt business as usual by not attending class or spending on campus."
A Cornell University student sits with a sign during a campus-wide sit-in on Oct. 7.
The sit-in comes two days after thousands of people took part in a campus rally protesting Cornell's handling of Jane Doe's allegations. Demonstrators held signs accusing the school of protecting the alleged rapists and demanding accountability.
#hours #student #university
"Seven hours for the seven hours she endured," a coalition of Cornell student groups said in an Instagram post announcing the demonstration. "Seven hours of solidarity. Seven hours demanding change."
About 80 students gathered in a campus dining hall named for Pulitzer Prize-winning author Toni Morrison on Wednesday afternoon, according to NBC News. The protest was part of "Zero Day," which organizers described as an "economic blackout calling on students to disrupt business as usual by not attending class or spending on campus."
A Cornell University student sits with a sign during a campus-wide sit-in on Oct. 7.
The sit-in comes two days after thousands of people took part in a campus rally protesting Cornell's handling of Jane Doe's allegations. Demonstrators held signs accusing the school of protecting the alleged rapists and demanding accountability.
#hours #student #university
1 month ago
MOSCOW, Oct 6 (Reuters) - Russia's health watchdog said on Tuesday that no cases of plague had been detected among people who had come into contact with a Siberian plague institute laboratory worker who died last week.
Authorities say the 28-year-old woman died on Friday from pneumonia of an as-yet unestablished origin, in a case that has prompted international concern, including from US President Donald Trump.
Rospotrebnadzor, the watchdog, said in a statement that no infectious diseases had been reported among the staff of the same plague research institute in Irkutsk over the past 10 days and that extensive testing had found no microorganisms in the deceased woman's body linked to her work.
Elena Sofina, deputy head of the Shelekhov district near Irkutsk, where a local hospital was placed under quarantine, said that what she called "a dangerous diagnosis" had not been confirmed.
She added that 60% of those placed under quarantine as a precaution had already been released. Local media said around 200 people had previously been quarantined.
#local #people #died
Authorities say the 28-year-old woman died on Friday from pneumonia of an as-yet unestablished origin, in a case that has prompted international concern, including from US President Donald Trump.
Rospotrebnadzor, the watchdog, said in a statement that no infectious diseases had been reported among the staff of the same plague research institute in Irkutsk over the past 10 days and that extensive testing had found no microorganisms in the deceased woman's body linked to her work.
Elena Sofina, deputy head of the Shelekhov district near Irkutsk, where a local hospital was placed under quarantine, said that what she called "a dangerous diagnosis" had not been confirmed.
She added that 60% of those placed under quarantine as a precaution had already been released. Local media said around 200 people had previously been quarantined.
#local #people #died
1 month ago
PUBLISHED
OCT 03, 2026 AT 07:38 PM EDT
Tennessee officials are still investigating why death row inmate Christa Pike survived an execution attempt after receiving two doses of pentobarbital, a drug intended to render a person unconscious and ultimately cause death.
While the immediate focus has been on what went wrong inside the execution chamber, experts say Pike's case has also renewed scrutiny of a problem that has been building for more than a decade: how states obtain lethal injection drugs after pharmaceutical companies moved aggressively to keep their products from being used in executions. Despite those efforts, pentobarbital remains the primary execution drug used by many death-penalty states, making questions about sourcing, testing and oversight especially significant.
The issue has reshaped how many states carry out executions, forcing them to change drug protocols, seek alternative suppliers and adopt increasingly secretive procurement practices.
#pentobarbital #executions #published #tennessee
OCT 03, 2026 AT 07:38 PM EDT
Tennessee officials are still investigating why death row inmate Christa Pike survived an execution attempt after receiving two doses of pentobarbital, a drug intended to render a person unconscious and ultimately cause death.
While the immediate focus has been on what went wrong inside the execution chamber, experts say Pike's case has also renewed scrutiny of a problem that has been building for more than a decade: how states obtain lethal injection drugs after pharmaceutical companies moved aggressively to keep their products from being used in executions. Despite those efforts, pentobarbital remains the primary execution drug used by many death-penalty states, making questions about sourcing, testing and oversight especially significant.
The issue has reshaped how many states carry out executions, forcing them to change drug protocols, seek alternative suppliers and adopt increasingly secretive procurement practices.
#pentobarbital #executions #published #tennessee
1 month ago
Opening a Bible that once belonged to Thomas Jefferson, staff at the Smithsonian National Museum of American History in 2011 discovered a reddish-blond hair pressed between the pages. That hair, suspected to have belonged to Jefferson himself, launched a DNA investigation spanning more than a decade that’s now providing a long-missing puzzle piece regarding Jefferson’s relationship with Sally Hemings, an enslaved woman in his household.
After spending years reconstructing DNA fragments, scientists have revealed the most compelling evidence to date that Jefferson, a founding father of the United States, also fathered children with Hemings — a relationship that has been long rumored but never definitively proven. How that investigation unfolded is documented in the book “History by a Hair: Thomas Jefferson, Sally Hemings & Solving a 200-Year-Old Mystery,” written by Richard Kurin, a distinguished scholar and ambassador-at-large at the Smithsonian, and published on September 22.
Kurin is also senior author of a paper describing the methods that connected the former US president to Hemings’ descendants, which involved delving deep into the genetics of the Jefferson and Hemings family trees. The paper, published September 21 on the preprint platform bioRXiv, has not yet been peer-reviewed.
In addition to testing the hair found in the Bible, the researchers also collected genetic material from multiple confirmed samples of Jefferson’s hair, held in the collection of the Smithsonian. They compared that with DNA from descendants of multiple lineages: Jefferson and his wife Martha, Jefferson’s brother Randolph, and two of Hemings’ sons, Eston and Madison. (Hemings had four children who lived to adulthood, but only Eston and Madison claimed Jefferson as their father).
Matches in the DNA suggest the chance that Thomas Jefferson fathered at least one of Sally Hemings’ children was 99.96%.
#jefferson #children #bible #history
After spending years reconstructing DNA fragments, scientists have revealed the most compelling evidence to date that Jefferson, a founding father of the United States, also fathered children with Hemings — a relationship that has been long rumored but never definitively proven. How that investigation unfolded is documented in the book “History by a Hair: Thomas Jefferson, Sally Hemings & Solving a 200-Year-Old Mystery,” written by Richard Kurin, a distinguished scholar and ambassador-at-large at the Smithsonian, and published on September 22.
Kurin is also senior author of a paper describing the methods that connected the former US president to Hemings’ descendants, which involved delving deep into the genetics of the Jefferson and Hemings family trees. The paper, published September 21 on the preprint platform bioRXiv, has not yet been peer-reviewed.
In addition to testing the hair found in the Bible, the researchers also collected genetic material from multiple confirmed samples of Jefferson’s hair, held in the collection of the Smithsonian. They compared that with DNA from descendants of multiple lineages: Jefferson and his wife Martha, Jefferson’s brother Randolph, and two of Hemings’ sons, Eston and Madison. (Hemings had four children who lived to adulthood, but only Eston and Madison claimed Jefferson as their father).
Matches in the DNA suggest the chance that Thomas Jefferson fathered at least one of Sally Hemings’ children was 99.96%.
#jefferson #children #bible #history
2 months ago
Choosing between a niche equipment provider and a diversified industry **** an requires balancing high growth potential against established stability. Here is how Aehr Test Systems (NASDAQ:AEHR) and KLA (NASDAQ:KLAC) compare for investors.
Aehr Test Systems focuses on specific stress-testing solutions for power semiconductors and memory, while KLA provides broad process control tools used across the entire chip-making industry. While they both operate in the same sector, their scale and risk profiles differ significantly, making them attractive to different types of portfolios.
Aehr Test Systems designs and sells specialized equipment for the testing and stabilization of semiconductor products in various forms, including wafers and singulated dies. The company focuses on the high-growth silicon carbide market for electric vehicles and high-bandwidth memory for artificial intelligence infrastructure. In its 2026 fiscal year (FY), which ended May 29, its five largest customers accounted for nearly 70% of net sales, and customer concentration like this adds a layer of risk to the business.
In FY 2026, revenue reached $50.0 million, representing a decline of 15.2% compared to the previous year. This contraction followed a period of higher operating costs, resulting in a net loss of $7.1 million for the period. The net margin, which represents the percentage of revenue remaining as profit after all expenses, was -14.3% in the latest fiscal year.
As of its May 2026 balance sheet, the debt-to-equity ratio is zero, indicating that the company has no debt relative to its shareholder equity. The current ratio, which measures a company's ability to cover short-term liabilities with short-term **** ets, is 10.3x. Free cash flow, defined as cash from operations minus capital expenditures, was a negative $5.4 million for the fiscal year ended in May.
#year #equipment
Aehr Test Systems focuses on specific stress-testing solutions for power semiconductors and memory, while KLA provides broad process control tools used across the entire chip-making industry. While they both operate in the same sector, their scale and risk profiles differ significantly, making them attractive to different types of portfolios.
Aehr Test Systems designs and sells specialized equipment for the testing and stabilization of semiconductor products in various forms, including wafers and singulated dies. The company focuses on the high-growth silicon carbide market for electric vehicles and high-bandwidth memory for artificial intelligence infrastructure. In its 2026 fiscal year (FY), which ended May 29, its five largest customers accounted for nearly 70% of net sales, and customer concentration like this adds a layer of risk to the business.
In FY 2026, revenue reached $50.0 million, representing a decline of 15.2% compared to the previous year. This contraction followed a period of higher operating costs, resulting in a net loss of $7.1 million for the period. The net margin, which represents the percentage of revenue remaining as profit after all expenses, was -14.3% in the latest fiscal year.
As of its May 2026 balance sheet, the debt-to-equity ratio is zero, indicating that the company has no debt relative to its shareholder equity. The current ratio, which measures a company's ability to cover short-term liabilities with short-term **** ets, is 10.3x. Free cash flow, defined as cash from operations minus capital expenditures, was a negative $5.4 million for the fiscal year ended in May.
#year #equipment
2 months ago
Interested in Keysight Technologies Inc.? Here are five stocks we like better.
AI data-center demand is driving strong growth in Keysight's wireline business, particularly around 1.6T and emerging 3.2T networking, silicon photonics, co-packaged optics and system-level testing.
Demand currently exceeds supply, with Keysight expanding manufacturing capacity, supplier agreements and component sourcing; revenue beyond its typical order-to-revenue window was approaching $100 million.
Keysight expects additional growth from 6G, aerospace and defense, semiconductors and software-defined vehicles. The company anticipates 6G acceleration in the first half of 2028 and plans to maintain investment while targeting incremental margins of at least 40% when growth exceeds 5%.
3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
#exceeds #lesser
AI data-center demand is driving strong growth in Keysight's wireline business, particularly around 1.6T and emerging 3.2T networking, silicon photonics, co-packaged optics and system-level testing.
Demand currently exceeds supply, with Keysight expanding manufacturing capacity, supplier agreements and component sourcing; revenue beyond its typical order-to-revenue window was approaching $100 million.
Keysight expects additional growth from 6G, aerospace and defense, semiconductors and software-defined vehicles. The company anticipates 6G acceleration in the first half of 2028 and plans to maintain investment while targeting incremental margins of at least 40% when growth exceeds 5%.
3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
#exceeds #lesser
2 months ago
Back in 2021, banks treated crypto like radioactive waste. Fast forward to 2026, and financial giant Visa (NYSE: V) isn't just dipping a toe in -- it's basically cannonballing into the deep end of the stablecoin pool.
Here's what Visa has done recently, and why it's huge for anyone holding crypto.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
In July, Visa introduced the Visa Stablecoin Platform (VSP). Think of it as a plug-and-play stablecoin toolkit for traditional banks and fintechs.
Instead of traditional institutions sweating over managing private keys, setting up multi-sig wallets, or figuring out how to mint and burn tokens, Visa handed them a slick "Wallet-as-a-Service." Starting with Open USD, an upcoming token, Visa will also support the popular USDC (CRYPTO: USDC) coin later this year. Banks can now hold, move, and settle stablecoins using the same enterprise-grade security tools they're already comfortable with. It's in beta testing for now, pending the Open USD launch.
#Crypto #stablecoin
Here's what Visa has done recently, and why it's huge for anyone holding crypto.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
In July, Visa introduced the Visa Stablecoin Platform (VSP). Think of it as a plug-and-play stablecoin toolkit for traditional banks and fintechs.
Instead of traditional institutions sweating over managing private keys, setting up multi-sig wallets, or figuring out how to mint and burn tokens, Visa handed them a slick "Wallet-as-a-Service." Starting with Open USD, an upcoming token, Visa will also support the popular USDC (CRYPTO: USDC) coin later this year. Banks can now hold, move, and settle stablecoins using the same enterprise-grade security tools they're already comfortable with. It's in beta testing for now, pending the Open USD launch.
#Crypto #stablecoin
2 months ago
On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
2 months ago
On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes.
Analysts said Amgen's olpasiran faces the clearest negative read-through given its similar trial design. Lilly's lepodisiran is being tested in a broader patient population that could limit how directly Novartis' failure applies. It is also described as less material to Lilly's overall valuation than pelacarsen was for Novartis.
Copyright: stocking / 123RF Stock Photo
Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) could still succeed where Novartis failed. Pelacarsen's failure does not establish that lowering Lp(a) cannot reduce cardiovascular events. **** ysts noted that Novartis' trial faced a high statistical hurdle and that Amgen's olpasiran and Lilly's lepodisiran have produced stronger Lp(a) reductions in earlier studies. Both companies also continue testing their drugs in specific patient populations with high Lp(a). It leaves room for their trials to produce different outcomes from Novartis' study.
Lilly's lepodisiran faces a less direct read-through than Amgen's olpasiran. **** ysts view Amgen's olpasiran as the closest comparison to pelacarsen because the programs use similar trial designs. Lilly's lepodisiran is being tested in an overall patient population. It could make Novartis' failure less directly applicable. **** ysts also view lepodisiran as less material to Lilly's overall valuation than pelacarsen was to Novartis. It reduces the potential financial impact of an unsuccessful outcome.
#lepodisiran #less
Analysts said Amgen's olpasiran faces the clearest negative read-through given its similar trial design. Lilly's lepodisiran is being tested in a broader patient population that could limit how directly Novartis' failure applies. It is also described as less material to Lilly's overall valuation than pelacarsen was for Novartis.
Copyright: stocking / 123RF Stock Photo
Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) could still succeed where Novartis failed. Pelacarsen's failure does not establish that lowering Lp(a) cannot reduce cardiovascular events. **** ysts noted that Novartis' trial faced a high statistical hurdle and that Amgen's olpasiran and Lilly's lepodisiran have produced stronger Lp(a) reductions in earlier studies. Both companies also continue testing their drugs in specific patient populations with high Lp(a). It leaves room for their trials to produce different outcomes from Novartis' study.
Lilly's lepodisiran faces a less direct read-through than Amgen's olpasiran. **** ysts view Amgen's olpasiran as the closest comparison to pelacarsen because the programs use similar trial designs. Lilly's lepodisiran is being tested in an overall patient population. It could make Novartis' failure less directly applicable. **** ysts also view lepodisiran as less material to Lilly's overall valuation than pelacarsen was to Novartis. It reduces the potential financial impact of an unsuccessful outcome.
#lepodisiran #less
2 months ago
Data center developer Crusoe said Thursday it raised $3.9 billion in a Series F round that pushes its valuation to $30.9 billion. The massive round was co-led by Atreides Management, Mubadala Capital, and Valor Equity Partners. Founders Fund, GIC, Nvidia, Qatar Investment Authority (QIA), Radical Ventures, and TPG also participated, according to Crusoe.
Crusoe also announced three new board members, including Cloudflare CFO Thomas Seifert; Bill Stein, partner and CIO at Primary Digital Infrastructure; and Redwood Materials founder and CEO JB Straubel, who also sits on Tesla's board. Straubel already has ties to Crusoe; he personally invested in the company in 2021, and Crusoe later became the first customer of Redwood's energy storage business.
The eight-year-old company's fresh capital infusion will help finance existing data center projects, including a large site in Abilene, Texas, used by OpenAI, as well as smaller, modular AI factories that can be transported by truck and connected to large power sources almost anywhere.
By manufacturing these modular data centers, called Spark, at its own facilities, Crusoe can deploy compute capacity quickly and without the need for large construction workforces. The smaller centers could also help Crusoe sidestep, at least in part, another major obstacle facing data center developers: backlash from local communities protesting massive complexes near their neighborhoods.
Crusoe co-founder and CEO Chase Lochmiller, who is pictured above, said in a statement he believes AI will usher in an era of abundance, but to get there will mean "controlling the infrastructure from electrons to tokens, and we're grateful to have investors who share that conviction."
#straubel #round
Crusoe also announced three new board members, including Cloudflare CFO Thomas Seifert; Bill Stein, partner and CIO at Primary Digital Infrastructure; and Redwood Materials founder and CEO JB Straubel, who also sits on Tesla's board. Straubel already has ties to Crusoe; he personally invested in the company in 2021, and Crusoe later became the first customer of Redwood's energy storage business.
The eight-year-old company's fresh capital infusion will help finance existing data center projects, including a large site in Abilene, Texas, used by OpenAI, as well as smaller, modular AI factories that can be transported by truck and connected to large power sources almost anywhere.
By manufacturing these modular data centers, called Spark, at its own facilities, Crusoe can deploy compute capacity quickly and without the need for large construction workforces. The smaller centers could also help Crusoe sidestep, at least in part, another major obstacle facing data center developers: backlash from local communities protesting massive complexes near their neighborhoods.
Crusoe co-founder and CEO Chase Lochmiller, who is pictured above, said in a statement he believes AI will usher in an era of abundance, but to get there will mean "controlling the infrastructure from electrons to tokens, and we're grateful to have investors who share that conviction."
#straubel #round
2 months ago
On September 9, 2026, Reuters reported that Meta Platforms, Inc. (NASDAQ:META) rolled out Muse, a long-touted AI agent that can autonomously send emails, sell a car, and book travel on a person's behalf, despite internal concerns among Meta's own employees that the technology mismanages access to sensitive personal data. The agent is modeled on the open-source system OpenClaw and available initially only in the U.S. through a dedicated app or WhatsApp. It is designed to access apps across email, calendar, payments, health, shopping, and smart-home categories as the centerpiece of CEO Mark Zuckerberg's "personal superintelligence" strategy.
Muse could give Meta Platforms, Inc. (NASDAQ:META) a new revenue stream beyond advertising by turning its massive user base into paying AI customers. The company launched Muse with a free tier and $20 and $100 monthly subscription options for heavier users. The agent can handle tasks such as sending emails, selling items, and booking travel. It gives Meta a direct way to monetize AI capabilities and diversify its revenue base.
The new AI agent could help Meta generate returns from its enormous AI infrastructure investment. Meta expects AI infrastructure spending to exceed $130 billion this year, increasing the importance of monetizing its AI capabilities. Meta can distribute Muse through WhatsApp and eventually connect it with smart glasses. It gives the company multiple ways to expand usage and build a broader consumer AI ecosystem.
Meta has strengthened Muse's safeguards before launching the product. It could support wider use. Meta delayed the launch from April to improve security and added an autonomous safety agent that monitors Muse's actions. Users can also control which apps Muse can access, while Meta plans an encrypted version. It gives the company a path to address security concerns as it expands the product.
Muse's security failures could damage consumer trust in a product that needs access to sensitive information. Internal testing uncovered an incident in which Muse exposed private iCloud photos. Employees also reported other security concerns. Such failures could discourage users from connecting email, payment, health, and other personal accounts, limiting subscription adoption and Meta Platforms, Inc. (NASDAQ:META)'s potential revenue from Muse.
#muse
Muse could give Meta Platforms, Inc. (NASDAQ:META) a new revenue stream beyond advertising by turning its massive user base into paying AI customers. The company launched Muse with a free tier and $20 and $100 monthly subscription options for heavier users. The agent can handle tasks such as sending emails, selling items, and booking travel. It gives Meta a direct way to monetize AI capabilities and diversify its revenue base.
The new AI agent could help Meta generate returns from its enormous AI infrastructure investment. Meta expects AI infrastructure spending to exceed $130 billion this year, increasing the importance of monetizing its AI capabilities. Meta can distribute Muse through WhatsApp and eventually connect it with smart glasses. It gives the company multiple ways to expand usage and build a broader consumer AI ecosystem.
Meta has strengthened Muse's safeguards before launching the product. It could support wider use. Meta delayed the launch from April to improve security and added an autonomous safety agent that monitors Muse's actions. Users can also control which apps Muse can access, while Meta plans an encrypted version. It gives the company a path to address security concerns as it expands the product.
Muse's security failures could damage consumer trust in a product that needs access to sensitive information. Internal testing uncovered an incident in which Muse exposed private iCloud photos. Employees also reported other security concerns. Such failures could discourage users from connecting email, payment, health, and other personal accounts, limiting subscription adoption and Meta Platforms, Inc. (NASDAQ:META)'s potential revenue from Muse.
#muse
2 months ago
On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's efforts to diversify beyond its blockbuster obesity and diabetes franchise.
The move follows a July disclosure that ziltivekimab failed to reduce major adverse cardiovascular events in a late-stage trial. An independent data monitoring committee found a "low likelihood" that the two additional heart-failure studies would produce a different result from that earlier failure, prompting Novo to end them ahead of schedule.
Novo Nordisk A/S (NYSE:NVO) still has one opportunity to create value from its cardiovascular program. The company will continue testing ziltivekimab in patients recovering from a heart attack, with results expected in the first half of 2027. A successful outcome could give Novo another growth opportunity outside its obesity and diabetes franchise.
Novo's core obesity and diabetes business remains the much larger driver of its financial performance. The oral Wegovy pill has already generated more than 2 million prescriptions shortly after its January 2026 launch. It gives Novo an important growth opportunity as the company competes with Eli Lilly in the oral GLP-1 market.
The company can also preserve capital by ending trials that show limited prospects for success. An independent data monitoring committee found a low likelihood that the two heart-failure studies would produce different results from the earlier failed trial. Novo can redirect the resources it would have spent on those studies toward higher-potential programs.
#obesity #diabetes
The move follows a July disclosure that ziltivekimab failed to reduce major adverse cardiovascular events in a late-stage trial. An independent data monitoring committee found a "low likelihood" that the two additional heart-failure studies would produce a different result from that earlier failure, prompting Novo to end them ahead of schedule.
Novo Nordisk A/S (NYSE:NVO) still has one opportunity to create value from its cardiovascular program. The company will continue testing ziltivekimab in patients recovering from a heart attack, with results expected in the first half of 2027. A successful outcome could give Novo another growth opportunity outside its obesity and diabetes franchise.
Novo's core obesity and diabetes business remains the much larger driver of its financial performance. The oral Wegovy pill has already generated more than 2 million prescriptions shortly after its January 2026 launch. It gives Novo an important growth opportunity as the company competes with Eli Lilly in the oral GLP-1 market.
The company can also preserve capital by ending trials that show limited prospects for success. An independent data monitoring committee found a low likelihood that the two heart-failure studies would produce different results from the earlier failed trial. Novo can redirect the resources it would have spent on those studies toward higher-potential programs.
#obesity #diabetes
2 months ago
On Wednesday, OpenAI (OPAI.PVT) revealed six new examples of its AI models displaying "unexpected or concerning model behavior" during testing and evaluation.
The company made the announcement alongside a new framework for "tracking, reporting, and disclosing" instances where AI models take actions they otherwise aren't told to or shouldn't.
It follows a number of reports of AI models from companies hacking into third-party networks and services, including an unreleased OpenAI model breaking into the network of AI model and testing site Hugging Face.
Earlier this week, Anthropic (ANTH.PVT) CEO Dario Amodei penned a lengthy essay calling for a slowdown in the pace of the development of frontier AI models, after Anthropic researcher Jacob ******* on posted on X that he was resigning from the company because it, and his former employer OpenAI, is "racing straight to self-improving superintelligence and gambling with our lives."
Anthropic alignment science lead Evan Hubinger followed up on ******* on's comments with his own post on X saying that he believes there is a greater-than-10% chance that the technology could "kill all humans."
#face
The company made the announcement alongside a new framework for "tracking, reporting, and disclosing" instances where AI models take actions they otherwise aren't told to or shouldn't.
It follows a number of reports of AI models from companies hacking into third-party networks and services, including an unreleased OpenAI model breaking into the network of AI model and testing site Hugging Face.
Earlier this week, Anthropic (ANTH.PVT) CEO Dario Amodei penned a lengthy essay calling for a slowdown in the pace of the development of frontier AI models, after Anthropic researcher Jacob ******* on posted on X that he was resigning from the company because it, and his former employer OpenAI, is "racing straight to self-improving superintelligence and gambling with our lives."
Anthropic alignment science lead Evan Hubinger followed up on ******* on's comments with his own post on X saying that he believes there is a greater-than-10% chance that the technology could "kill all humans."
#face
2 months ago
On September 11, a caller praised The Boeing Company's (NYSE:BA) CEO and asked when the company would overcome the ongoing labor uncertainty and finally move beyond years of sideways stock performance. Mad Money host Jim Cramer replied:
I think that Boeing is ready to go up. But here's the problem. Every time crude goes up a dollar, the stock goes down a dollar. And that, think about it, that was actually the ratio. I did some work on this. And because today crude was down, Boeing went up $5... No, it's so stupid because, in truth, the airlines need more planes because the planes are more fuel-efficient. So they actually do better in this environment, but ******* ody cares. They know that airlines have to borrow money to buy planes and rates are higher, and they think that oil somehow's bad. But what ends up happening is the stock does nothing. I think it's about to go up because I think oil might be peaking unless there's some catastrophe over there.
The Boeing Company's (NYSE:BA) second-quarter results showed improving cash generation, but profitability remained weak. Revenue rose 8% year over year to $24.6 billion, while operating cash flow reached $1.4 billion and free cash flow was $631 million. Its total backlog reached a record $715 billion, including more than 6,200 commercial airplanes. CEO Kelly Ortberg said, "We're ramping up production just as we planned. That's driving higher revenues and improved cash flow." He also said there's more work ahead to ramp production, complete commercial-aircraft certifications and uphold customer commitments. Boeing said the 737-7 and 737-10 had completed flight testing, with deliveries expected to begin in 2027.
The Boeing Company's (NYSE:BA) large backlog has yet to translate into consistent commercial-aircraft profitability, leaving execution and margins as important concerns for investors. Commercial Airplanes delivered 171 aircraft in the second quarter but still posted a $322 million operating loss and a negative 2.7% operating margin. It also reported a $428 million GAAP net loss.
The balance sheet leaves less room for further setbacks. The company ended June with $45.9 billion of consolidated debt against $20 billion of cash and investments in marketable securities. The FAA certified the 737-7 on August 3, while Boeing continues working toward certification of the 737-10. First deliveries of the variants are expected in 2027. The company also recorded $280 million of losses on the VC-25B program in the quarter.
#boeing #cash #commercial
I think that Boeing is ready to go up. But here's the problem. Every time crude goes up a dollar, the stock goes down a dollar. And that, think about it, that was actually the ratio. I did some work on this. And because today crude was down, Boeing went up $5... No, it's so stupid because, in truth, the airlines need more planes because the planes are more fuel-efficient. So they actually do better in this environment, but ******* ody cares. They know that airlines have to borrow money to buy planes and rates are higher, and they think that oil somehow's bad. But what ends up happening is the stock does nothing. I think it's about to go up because I think oil might be peaking unless there's some catastrophe over there.
The Boeing Company's (NYSE:BA) second-quarter results showed improving cash generation, but profitability remained weak. Revenue rose 8% year over year to $24.6 billion, while operating cash flow reached $1.4 billion and free cash flow was $631 million. Its total backlog reached a record $715 billion, including more than 6,200 commercial airplanes. CEO Kelly Ortberg said, "We're ramping up production just as we planned. That's driving higher revenues and improved cash flow." He also said there's more work ahead to ramp production, complete commercial-aircraft certifications and uphold customer commitments. Boeing said the 737-7 and 737-10 had completed flight testing, with deliveries expected to begin in 2027.
The Boeing Company's (NYSE:BA) large backlog has yet to translate into consistent commercial-aircraft profitability, leaving execution and margins as important concerns for investors. Commercial Airplanes delivered 171 aircraft in the second quarter but still posted a $322 million operating loss and a negative 2.7% operating margin. It also reported a $428 million GAAP net loss.
The balance sheet leaves less room for further setbacks. The company ended June with $45.9 billion of consolidated debt against $20 billion of cash and investments in marketable securities. The FAA certified the 737-7 on August 3, while Boeing continues working toward certification of the 737-10. First deliveries of the variants are expected in 2027. The company also recorded $280 million of losses on the VC-25B program in the quarter.
#boeing #cash #commercial
2 months ago
Oddity Tech Ltd. (NASDAQ:ODD) reported second-quarter revenue of approximately $181 million on September 9, down 25% from $241 million a year earlier. Company-defined non-GAAP adjusted EBITDA fell to $13 million from $70 million. This measure excludes net financial income, income taxes, depreciation and amortization, share-based compensation, and certain unusual or nonrecurring items from net income.
Management attributed the disruption primarily to an advertising-algorithm problem affecting IL MAKIAGE. Oddity Tech Ltd. (NASDAQ:ODD) expects third-quarter revenue to decline approximately 5% year over year, with adjusted EBITDA of $18 million to $20 million. The sequential improvement describes a narrowing year-over-year revenue decline.
Management's diagnosis centers on distorted advertising signals that impair IL MAKIAGE's ability to reach suitable customers at acceptable acquisition costs. Oddity Tech Ltd. (NASDAQ:ODD) is testing changes with its largest advertising partner to retrain the algorithm. If those changes restore profitable customer acquisition, the existing brand could recover without a fundamental overhaul of its products.
Other brands provide operating evidence beyond that hypothesis. SpoiledChild delivered double-digit quarterly revenue growth, and management expects at least 35% growth for 2026, approaching $350 million in revenue. Management expects METHODIQ's first-year revenue to exceed SpoiledChild's first-year result.
These results support the argument that Oddity Tech Ltd. (NASDAQ:ODD) can build additional brands using its technology platform. A broader sales base could gradually reduce dependence on IL MAKIAGE, while successful customer retention would help recover upfront advertising spending over multiple purchases.
#revenue #NASDAQ #advertising #expects
Management attributed the disruption primarily to an advertising-algorithm problem affecting IL MAKIAGE. Oddity Tech Ltd. (NASDAQ:ODD) expects third-quarter revenue to decline approximately 5% year over year, with adjusted EBITDA of $18 million to $20 million. The sequential improvement describes a narrowing year-over-year revenue decline.
Management's diagnosis centers on distorted advertising signals that impair IL MAKIAGE's ability to reach suitable customers at acceptable acquisition costs. Oddity Tech Ltd. (NASDAQ:ODD) is testing changes with its largest advertising partner to retrain the algorithm. If those changes restore profitable customer acquisition, the existing brand could recover without a fundamental overhaul of its products.
Other brands provide operating evidence beyond that hypothesis. SpoiledChild delivered double-digit quarterly revenue growth, and management expects at least 35% growth for 2026, approaching $350 million in revenue. Management expects METHODIQ's first-year revenue to exceed SpoiledChild's first-year result.
These results support the argument that Oddity Tech Ltd. (NASDAQ:ODD) can build additional brands using its technology platform. A broader sales base could gradually reduce dependence on IL MAKIAGE, while successful customer retention would help recover upfront advertising spending over multiple purchases.
#revenue #NASDAQ #advertising #expects
2 months ago
Cadence Design Systems (CDNS) trades at 54.5 times trailing earnings. A multiple that high is a requirement rather than an opinion. The price only works if the business grows into it, and you can work out exactly how much growth it takes. The harder question is whether that calculation deserves your trust here.
What Is Cadence's Price Already ***** uming?
Three things have to be true, and none is a forecast. Each is an ***** umption the price has already made, and each one is worth testing.
First, the market gives Cadence four years to grow into the multiple. Second, the multiple then settles at 28.8 times, where a mature, scaled software franchise usually lands. Third, net margin holds near 24.3%, roughly where Cadence's net margin has run over the past twelve months.
So How Fast Would Cadence Have To Grow?
#times #design
What Is Cadence's Price Already ***** uming?
Three things have to be true, and none is a forecast. Each is an ***** umption the price has already made, and each one is worth testing.
First, the market gives Cadence four years to grow into the multiple. Second, the multiple then settles at 28.8 times, where a mature, scaled software franchise usually lands. Third, net margin holds near 24.3%, roughly where Cadence's net margin has run over the past twelve months.
So How Fast Would Cadence Have To Grow?
#times #design
2 months ago
STERIS plc (STE), with a market capitalization of approximately $20.8 billion, is a global healthcare company focused on infection prevention and patient care. The Mentor, Ohio-based company provides consumable products, capital equipment, maintenance and repair services, sterilization solutions, laboratory testing, outsourced reprocessing, and operating room connectivity solutions.
Companies worth between $10 billion and $200 billion are generally classified as "large-cap stocks," and STERIS fits this description, with its market capitalization reflecting its substantial size and established position within the healthcare sector. STERIS stands out by combining a leading position in infection prevention with a broad range of healthcare and sterilization products and services. Its trusted brand, loyal customer base, strong financial position, and strategic acquisitions strengthen its competitive position while supporting continued expansion and innovation.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares
#steris #position
Companies worth between $10 billion and $200 billion are generally classified as "large-cap stocks," and STERIS fits this description, with its market capitalization reflecting its substantial size and established position within the healthcare sector. STERIS stands out by combining a leading position in infection prevention with a broad range of healthcare and sterilization products and services. Its trusted brand, loyal customer base, strong financial position, and strategic acquisitions strengthen its competitive position while supporting continued expansion and innovation.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares
#steris #position
2 months ago
Teradyne, Inc. (TER) is a technology company that designs and manufactures automated test equipment and advanced robotics systems, with a market capitalization of approximately $51.5 billion. Based in North Reading, Massachusetts, the company's semiconductor and electronics testing solutions help customers maintain quality standards, while its collaborative and mobile robots support manufacturing and warehouse operations across businesses of various sizes.
Companies valued between $10 billion and $200 billion are generally classified as "large-cap stocks," and Teradyne comfortably fits this category. Its edge comes from its leading role in automated testing and robotics, serving several industries, from semiconductors to automotive and aerospace. Its diversified product portfolio, strong brand, stable revenue, healthy profit margins, and consistent cash generation support continued investment in technology and long-term growth.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares
#robotics #support
Companies valued between $10 billion and $200 billion are generally classified as "large-cap stocks," and Teradyne comfortably fits this category. Its edge comes from its leading role in automated testing and robotics, serving several industries, from semiconductors to automotive and aerospace. Its diversified product portfolio, strong brand, stable revenue, healthy profit margins, and consistent cash generation support continued investment in technology and long-term growth.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares
#robotics #support
2 months ago
A public company typically has limited control over third-party financial products that reference its shares, but Robinhood Markets, Inc. (NASDAQ:HOOD) and AMC Entertainment Holdings, Inc. (NYSE:AMC) are now testing that notion in public, in one of the year's most intense corporate spats. The debate revolves over stock tokens and has evolved from a heated social media post on September 3 to a live televised retort by September 9.
Robinhood Markets, Inc. (NASDAQ:HOOD) expanded its tokenized shares offering, which is issued through a unit named Robinhood ****** ets (Jersey) Limited and traded on Robinhood's proprietary blockchain, Robinhood Chain, to include over 190 public firms, including AMC, without the companies directly signing on. When AMC CEO Adam Aron discovered that his company was among them, he did not mince words. On September 3, Aron posted on X, calling the practice "contemptible, outrageous, disgusting, detestable, inexcusable, vile," questioning how it could possibly be legal, and stating that AMC Entertainment Holdings, Inc. (NYSE:AMC) had no relation to the tokens and did not condone them.
He stated that the company would retain independent securities counsel and vowed to take the matter to the SEC, characterizing Robinhood's tokens as an unregistered securities product that undermines the regular relationship between a public company and its shareholders.
The market reaction was fast and telling: AMC shares rose as much as 21% in overnight trading after the public dispute broke out.
Robinhood did not back down. In the days that followed, the company's chief legal officer, Dan Gallagher, a former SEC commissioner, mocked the tone of Aron's complaint on social media, saying Robinhood "know[s] a little something about the US securities laws," and inviting AMC's lawyers to contact them. CEO Vlad Tenev originally commented on X with a brief "What's the concern?" before making his first extensive, broadcast comments on the controversy in a CNBC "Squawk Box" interview on September 9.
#company
Robinhood Markets, Inc. (NASDAQ:HOOD) expanded its tokenized shares offering, which is issued through a unit named Robinhood ****** ets (Jersey) Limited and traded on Robinhood's proprietary blockchain, Robinhood Chain, to include over 190 public firms, including AMC, without the companies directly signing on. When AMC CEO Adam Aron discovered that his company was among them, he did not mince words. On September 3, Aron posted on X, calling the practice "contemptible, outrageous, disgusting, detestable, inexcusable, vile," questioning how it could possibly be legal, and stating that AMC Entertainment Holdings, Inc. (NYSE:AMC) had no relation to the tokens and did not condone them.
He stated that the company would retain independent securities counsel and vowed to take the matter to the SEC, characterizing Robinhood's tokens as an unregistered securities product that undermines the regular relationship between a public company and its shareholders.
The market reaction was fast and telling: AMC shares rose as much as 21% in overnight trading after the public dispute broke out.
Robinhood did not back down. In the days that followed, the company's chief legal officer, Dan Gallagher, a former SEC commissioner, mocked the tone of Aron's complaint on social media, saying Robinhood "know[s] a little something about the US securities laws," and inviting AMC's lawyers to contact them. CEO Vlad Tenev originally commented on X with a brief "What's the concern?" before making his first extensive, broadcast comments on the controversy in a CNBC "Squawk Box" interview on September 9.
#company
2 months ago
Interested in NVIDIA Corporation? Here are five stocks we like better.
NVIDIA released CUDA-Q Logical, an open-source software layer that links GPUs with quantum processors to solve practical error correction challenges.
Early testing by Fermilab and Sandia National Laboratories shows dramatic efficiency gains, including a seven-fold faster design cycle and reduced physical qubit requirements.
Quantum hardware firms IonQ, Rigetti Computing, and D-Wave Quantum could benefit as standardized software lowers development costs and enables deeper integration with NVIDIA's infrastructure.
Many investors view quantum hardware developers and classical semiconductor leaders as competing forces in high-performance computing. Recent developments demonstrate that the two architectures are becoming deeply interdependent.
#hardware #here
NVIDIA released CUDA-Q Logical, an open-source software layer that links GPUs with quantum processors to solve practical error correction challenges.
Early testing by Fermilab and Sandia National Laboratories shows dramatic efficiency gains, including a seven-fold faster design cycle and reduced physical qubit requirements.
Quantum hardware firms IonQ, Rigetti Computing, and D-Wave Quantum could benefit as standardized software lowers development costs and enables deeper integration with NVIDIA's infrastructure.
Many investors view quantum hardware developers and classical semiconductor leaders as competing forces in high-performance computing. Recent developments demonstrate that the two architectures are becoming deeply interdependent.
#hardware #here
2 months ago
Broyhill ******* et Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index's 15.1% and the MSCI ACWI Value Index's 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The letter highlights that a significant portion of the shortfall occurred in April due to market dynamics and geopolitical events, with tech, particularly semiconductors, driving recent gains. Broyhill notes its lack of direct semiconductor exposure but acknowledges potential interest in the sector if opportunities arise, maintaining its investment philosophy focused on capital protection in fragile market conditions. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Broyhill ******* et Management highlighted Sotera Health Company (NASDAQ:SHC). Sotera Health Company (NASDAQ:SHC), a US-based company that provides sterilization solutions, lab testing, and advisory services for the healthcare industry, contributed positively to the portfolio's performance this quarter. On September 14, 2026, Sotera Health Company (NASDAQ:SHC) closed at $18.52 per share, reflecting a market capitalization of $5.29 billion. Sotera Health Company (NASDAQ:SHC) posted a one-month return of 0.05%, while its shares gained 13.62% over the past 52 weeks.
Broyhill ******* et Management stated the following regarding Sotera Health Company (NASDAQ:SHC) in its Q2 2026 investor letter:
"Sotera Health Company (NASDAQ:SHC) was our largest contributor, with shares gaining 25%. We bought it in the first quarter, when the litigation docket was the only thing anyone wanted to discuss, and the price gave no weight to the fact that there are only two companies of scale doing this work. Results beat on revenue, adjusted EBITDA, and earnings per share; guidance was reaffirmed across every line, and management described March as its best volume month in three to four years. The EPA has proposed a full repeal of the 2024 ethylene oxide standard. At the time, the shares traded at roughly 14x forward earnings against 20x for the closest comparable."
Sotera Health Company (NASDAQ:SHC) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 43 hedge fund portfolios held Sotera Health Company (NASDAQ:SHC) at the end of the second quarter, compared to 42 in the previous quarter. While we acknowledge the potential of Sotera Health Company (NASDAQ:SHC) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#sotera #broyhill #second
In its second-quarter 2026 investor letter, Broyhill ******* et Management highlighted Sotera Health Company (NASDAQ:SHC). Sotera Health Company (NASDAQ:SHC), a US-based company that provides sterilization solutions, lab testing, and advisory services for the healthcare industry, contributed positively to the portfolio's performance this quarter. On September 14, 2026, Sotera Health Company (NASDAQ:SHC) closed at $18.52 per share, reflecting a market capitalization of $5.29 billion. Sotera Health Company (NASDAQ:SHC) posted a one-month return of 0.05%, while its shares gained 13.62% over the past 52 weeks.
Broyhill ******* et Management stated the following regarding Sotera Health Company (NASDAQ:SHC) in its Q2 2026 investor letter:
"Sotera Health Company (NASDAQ:SHC) was our largest contributor, with shares gaining 25%. We bought it in the first quarter, when the litigation docket was the only thing anyone wanted to discuss, and the price gave no weight to the fact that there are only two companies of scale doing this work. Results beat on revenue, adjusted EBITDA, and earnings per share; guidance was reaffirmed across every line, and management described March as its best volume month in three to four years. The EPA has proposed a full repeal of the 2024 ethylene oxide standard. At the time, the shares traded at roughly 14x forward earnings against 20x for the closest comparable."
Sotera Health Company (NASDAQ:SHC) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 43 hedge fund portfolios held Sotera Health Company (NASDAQ:SHC) at the end of the second quarter, compared to 42 in the previous quarter. While we acknowledge the potential of Sotera Health Company (NASDAQ:SHC) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#sotera #broyhill #second
2 months ago
Broyhill ****** et Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index's 15.1% and the MSCI ACWI Value Index's 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The letter highlights that a significant portion of the shortfall occurred in April due to market dynamics and geopolitical events, with tech, particularly semiconductors, driving recent gains. Broyhill notes its lack of direct semiconductor exposure but acknowledges potential interest in the sector if opportunities arise, maintaining its investment philosophy focused on capital protection in fragile market conditions. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Broyhill ****** et Management highlighted Sotera Health Company (NASDAQ:SHC). Sotera Health Company (NASDAQ:SHC), a US-based company that provides sterilization solutions, lab testing, and advisory services for the healthcare industry, contributed positively to the portfolio's performance this quarter. On September 14, 2026, Sotera Health Company (NASDAQ:SHC) closed at $18.52 per share, reflecting a market capitalization of $5.29 billion. Sotera Health Company (NASDAQ:SHC) posted a one-month return of 0.05%, while its shares gained 13.62% over the past 52 weeks.
Broyhill ****** et Management stated the following regarding Sotera Health Company (NASDAQ:SHC) in its Q2 2026 investor letter:
"Sotera Health Company (NASDAQ:SHC) was our largest contributor, with shares gaining 25%. We bought it in the first quarter, when the litigation docket was the only thing anyone wanted to discuss, and the price gave no weight to the fact that there are only two companies of scale doing this work. Results beat on revenue, adjusted EBITDA, and earnings per share; guidance was reaffirmed across every line, and management described March as its best volume month in three to four years. The EPA has proposed a full repeal of the 2024 ethylene oxide standard. At the time, the shares traded at roughly 14x forward earnings against 20x for the closest comparable."
Sotera Health Company (NASDAQ:SHC) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 43 hedge fund portfolios held Sotera Health Company (NASDAQ:SHC) at the end of the second quarter, compared to 42 in the previous quarter. While we acknowledge the potential of Sotera Health Company (NASDAQ:SHC) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#letter
In its second-quarter 2026 investor letter, Broyhill ****** et Management highlighted Sotera Health Company (NASDAQ:SHC). Sotera Health Company (NASDAQ:SHC), a US-based company that provides sterilization solutions, lab testing, and advisory services for the healthcare industry, contributed positively to the portfolio's performance this quarter. On September 14, 2026, Sotera Health Company (NASDAQ:SHC) closed at $18.52 per share, reflecting a market capitalization of $5.29 billion. Sotera Health Company (NASDAQ:SHC) posted a one-month return of 0.05%, while its shares gained 13.62% over the past 52 weeks.
Broyhill ****** et Management stated the following regarding Sotera Health Company (NASDAQ:SHC) in its Q2 2026 investor letter:
"Sotera Health Company (NASDAQ:SHC) was our largest contributor, with shares gaining 25%. We bought it in the first quarter, when the litigation docket was the only thing anyone wanted to discuss, and the price gave no weight to the fact that there are only two companies of scale doing this work. Results beat on revenue, adjusted EBITDA, and earnings per share; guidance was reaffirmed across every line, and management described March as its best volume month in three to four years. The EPA has proposed a full repeal of the 2024 ethylene oxide standard. At the time, the shares traded at roughly 14x forward earnings against 20x for the closest comparable."
Sotera Health Company (NASDAQ:SHC) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 43 hedge fund portfolios held Sotera Health Company (NASDAQ:SHC) at the end of the second quarter, compared to 42 in the previous quarter. While we acknowledge the potential of Sotera Health Company (NASDAQ:SHC) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#letter
2 months ago
The New York City Health Department has ordered 10 cooling towers in the South Bronx, including one at Yankee Stadium, to be cleaned and disinfected after preliminary testing found the presence of Legionella bacteria as officials investigate a cluster. NBC News medical contributor Natalie Azar discusses how the test was conducted the possible threat level to attendees.
#stadium
#stadium
2 months ago
On September 10, 1-800-Flowers.com Inc. (NASDAQ:FLWS) reported fiscal 2026 results that read like a company still finding its footing after a hard year. Full year revenue fell 10.8% to $1.5 billion, and the fourth quarter alone dropped 12.9% to $293.1 million, as consumers stayed selective with discretionary spending on gifts and gourmet food. Buried under those declines, though, is a different story: inventory shrank, free cash flow improved by $55 million, and the company hit a two-year cost savings target a full year early. The question now is whether that discipline can outrun the sales slide.
1-800-Flowers spent fiscal 2026 tearing down the walls between its brands. Instead of separate teams running each brand in silos, the company shifted to functional teams built around marketing, merchandising, and the digital shopping experience, with one team now acting as store manager for every website. That shift already shows up in products: the floral business combined its florist-fulfilled and direct-ship merchandising teams, so the same popular arrangements are available either way, instead of competing against itself on one landing page. Harry & David rolled out a redesigned, mobile-first website with AI-powered search that is currently in A/B testing, and several low-traffic standalone sites were folded into harryanddavid.com to concentrate traffic rather than split it.
The financial discipline behind that reorganization is real. The company reached its $50 million cost savings run rate a full year ahead of schedule and has already lined up another $15 million to $20 million in savings for fiscal 2027, with the full benefit landing in fiscal 2028. That, combined with tighter working capital management, pushed free cash flow up $55 million year over year and cut inventory to $153 million from $177 million. Average order value rose 5.5%, third-party marketplace sales through Amazon, Walmart, and DoorDash are growing at double-to-triple-digit rates and are already contribution margin positive, and BloomNet grew 1.9% on the back of local delivery partnerships with apps like DoorDash and Instacart.
The rest of the story is bleaker. Total transactions fell 17.6% for the year, and the fourth quarter's decline was broad-based: consumer floral and gifts dropped 13.4% to $182.8 million as the company pulled back on promotional discounting, and gourmet foods and gift baskets fell 15.4% to $85.8 million, a decline made worse by the timing of Easter. Adjusted EBITDA for the year collapsed to $2.9 million from $29.2 million, and adjusted gross margin slipped 110 basis points to 38%. Even the fourth quarter's 34.7% gross margin leaned on a one-time $7 million tariff refund.
#fiscal
1-800-Flowers spent fiscal 2026 tearing down the walls between its brands. Instead of separate teams running each brand in silos, the company shifted to functional teams built around marketing, merchandising, and the digital shopping experience, with one team now acting as store manager for every website. That shift already shows up in products: the floral business combined its florist-fulfilled and direct-ship merchandising teams, so the same popular arrangements are available either way, instead of competing against itself on one landing page. Harry & David rolled out a redesigned, mobile-first website with AI-powered search that is currently in A/B testing, and several low-traffic standalone sites were folded into harryanddavid.com to concentrate traffic rather than split it.
The financial discipline behind that reorganization is real. The company reached its $50 million cost savings run rate a full year ahead of schedule and has already lined up another $15 million to $20 million in savings for fiscal 2027, with the full benefit landing in fiscal 2028. That, combined with tighter working capital management, pushed free cash flow up $55 million year over year and cut inventory to $153 million from $177 million. Average order value rose 5.5%, third-party marketplace sales through Amazon, Walmart, and DoorDash are growing at double-to-triple-digit rates and are already contribution margin positive, and BloomNet grew 1.9% on the back of local delivery partnerships with apps like DoorDash and Instacart.
The rest of the story is bleaker. Total transactions fell 17.6% for the year, and the fourth quarter's decline was broad-based: consumer floral and gifts dropped 13.4% to $182.8 million as the company pulled back on promotional discounting, and gourmet foods and gift baskets fell 15.4% to $85.8 million, a decline made worse by the timing of Easter. Adjusted EBITDA for the year collapsed to $2.9 million from $29.2 million, and adjusted gross margin slipped 110 basis points to 38%. Even the fourth quarter's 34.7% gross margin leaned on a one-time $7 million tariff refund.
#fiscal
2 months ago
Nathan Fielder's upcoming documentary on Theranos founder Elizabeth Holmes has caused some strong reactions online, and now it's become one of the biggest meme formats of the year.
The memes are all about the people in our lives who swear they're not deceiving us when we know deep down that they are, and some of them hit a little too close to home.
So, what is the Elizabeth Holmes and Nathan Fielder "Why Would I Deceive You?" meme, and what is the context behind it? Here's what you need to know.
The teaser trailer for Nathan Fielder's documentary You Can See Everything was released on September 6th, 2026, and the documentary follows disgraced former Theranos CEO Elizabeth Holmes days before her arrest for fraud related to the company.
For those who don't know, Theranos claimed to have revolutionary blood-testing technology that, after investigations, did not do what it was advertised to do. In the years following the fraud exposure, the company was ultimately dissolved, and Holmes was convicted of defrauding investors.
#company
The memes are all about the people in our lives who swear they're not deceiving us when we know deep down that they are, and some of them hit a little too close to home.
So, what is the Elizabeth Holmes and Nathan Fielder "Why Would I Deceive You?" meme, and what is the context behind it? Here's what you need to know.
The teaser trailer for Nathan Fielder's documentary You Can See Everything was released on September 6th, 2026, and the documentary follows disgraced former Theranos CEO Elizabeth Holmes days before her arrest for fraud related to the company.
For those who don't know, Theranos claimed to have revolutionary blood-testing technology that, after investigations, did not do what it was advertised to do. In the years following the fraud exposure, the company was ultimately dissolved, and Holmes was convicted of defrauding investors.
#company
2 months ago
Howmet Aerospace Inc. (NYSE:HWM) is facing a mixed outlook after GE Aerospace agreed to acquire Consolidated Precision Products (CPP) for about $11.75 billion to secure more control over critical engine castings and expand production capacity. The announcement initially hit Howmet shares, which fell about 10%, as investors worried that GE could eventually rely less on outside suppliers such as Howmet.
However, Howmet CEO John Plant said he is comfortable with the deal and remains confident in Howmet's ability to grow. The bigger issue for Howmet right now appears to be how quickly it can expand capacity to keep up with soaring demand. Commercial aircraft production, defense activity and aftermarket demand are all increasing, while Howmet is also benefiting from demand for turbine components used in data centers. Plant said the scale of the required capital expansion is itself "testing" the company.
The strongest bullish argument for Howmet Aerospace Inc. (NYSE:HWM) is that GE's decision to spend nearly $12 billion on CPP validates how strategically valuable aerospace castings and engine components have become. The acquisition is aimed at addressing a supply bottleneck rather than signaling weak demand. GE expects airfoil demand to rise by more than 30% through 2030, while aircraft manufacturers and defense customers continue to push production higher. That creates a favorable industry backdrop for Howmet as well.
Howmet also has an opportunity to benefit from customers looking for additional capacity outside GE's newly integrated supply chain. If demand continues to exceed available casting capacity, Howmet's existing manufacturing footprint and expertise could give it significant pricing power and support further investment. Plant's comments that the company is being "tested" by the sheer scale of expansion suggest that Howmet is dealing with a capacity problem caused by strong demand, rather than a lack of orders.
Another positive is that Howmet Aerospace Inc. (NYSE:HWM)'s exposure extends beyond commercial aircraft. Its blades and vanes are also used in gas turbines serving the rapidly expanding data-center market, providing another avenue for growth alongside aerospace. Plant has also indicated that the company intends to revisit its longer-term revenue targets, after previously saying revenue could potentially double from 2025 levels within three to five years.
#commercial
However, Howmet CEO John Plant said he is comfortable with the deal and remains confident in Howmet's ability to grow. The bigger issue for Howmet right now appears to be how quickly it can expand capacity to keep up with soaring demand. Commercial aircraft production, defense activity and aftermarket demand are all increasing, while Howmet is also benefiting from demand for turbine components used in data centers. Plant said the scale of the required capital expansion is itself "testing" the company.
The strongest bullish argument for Howmet Aerospace Inc. (NYSE:HWM) is that GE's decision to spend nearly $12 billion on CPP validates how strategically valuable aerospace castings and engine components have become. The acquisition is aimed at addressing a supply bottleneck rather than signaling weak demand. GE expects airfoil demand to rise by more than 30% through 2030, while aircraft manufacturers and defense customers continue to push production higher. That creates a favorable industry backdrop for Howmet as well.
Howmet also has an opportunity to benefit from customers looking for additional capacity outside GE's newly integrated supply chain. If demand continues to exceed available casting capacity, Howmet's existing manufacturing footprint and expertise could give it significant pricing power and support further investment. Plant's comments that the company is being "tested" by the sheer scale of expansion suggest that Howmet is dealing with a capacity problem caused by strong demand, rather than a lack of orders.
Another positive is that Howmet Aerospace Inc. (NYSE:HWM)'s exposure extends beyond commercial aircraft. Its blades and vanes are also used in gas turbines serving the rapidly expanding data-center market, providing another avenue for growth alongside aerospace. Plant has also indicated that the company intends to revisit its longer-term revenue targets, after previously saying revenue could potentially double from 2025 levels within three to five years.
#commercial
2 months ago
CHATTANOOGA, Tenn. — Kenco opened a 30,000-square-foot Innovation Lab on Sept. 10, tripling a testing footprint the third-party logistics provider first built in 2015.
The larger facility allows Kenco to run warehouse automation testing on larger and more complex systems. It also allows more of those systems to run side by side. Testing takes place inside a building designed to mirror real-world warehouse conditions so results carry over to a live distribution center.
Ainsley Williams, vice president of automation and innovation at Kenco, described the expansion as benefiting both manufacturers and customers.
"The Innovation Lab has long stood as the convergence point for leading technologies and real-world applications, helping both manufacturers and customers identify and realize what's possible," Williams said. "By tripling our innovation footprint, we can further provide a ***** e for OEMs to continue experimenting with their products in a real environment and for customers to explore product and value without having to invest in them."
The original lab was created to help the company understand how emerging technologies such as automation would affect its operations.
#real #customers #larger
The larger facility allows Kenco to run warehouse automation testing on larger and more complex systems. It also allows more of those systems to run side by side. Testing takes place inside a building designed to mirror real-world warehouse conditions so results carry over to a live distribution center.
Ainsley Williams, vice president of automation and innovation at Kenco, described the expansion as benefiting both manufacturers and customers.
"The Innovation Lab has long stood as the convergence point for leading technologies and real-world applications, helping both manufacturers and customers identify and realize what's possible," Williams said. "By tripling our innovation footprint, we can further provide a ***** e for OEMs to continue experimenting with their products in a real environment and for customers to explore product and value without having to invest in them."
The original lab was created to help the company understand how emerging technologies such as automation would affect its operations.
#real #customers #larger
